Plasma-based antigen persistence in the post-acute phase of COVID-19.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier Science Country of Publication: United States NLM ID: 101130150 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-4457 (Electronic) Linking ISSN: 14733099 NLM ISO Abbreviation: Lancet Infect Dis Subsets: MEDLINE
    • Publication Information:
      Original Publication: New York, NY : Elsevier Science ; The Lancet Pub. Group, 2001-
    • Subject Terms:
      COVID-19*/immunology ; SARS-CoV-2*/immunology; Humans ; Antigens, Viral/immunology ; Antigens, Viral/blood ; Antibodies, Viral/blood ; Male ; Middle Aged ; Female
    • Abstract:
      Competing Interests: MJP reports consulting for Gilead Sciences and AstraZeneca and reports research support from Aerium Therapeutics outside the submitted work. SGD reports consulting for Enanta Pharmaceuticals and Pfizer and reports research support from Aerium Therapeutics outside the submitted work. DRW has a financial interest in Quanterix Corporation, a company that develops an ultra-sensitive digital immunoassay platform and is an inventor of the Simoa technology, reports being a founder of Quanterix Corporation, and also serves on its Board of Directors. DRW's interests were reviewed and are managed by Mass General Brigham and Harvard University in accordance with their conflict of interest policies. All other authors declare no competing interests. This work was supported with funding from the PolyBio Research Foundation for the LIINC Clinical Core and was supported by NIH/NIAID 3R01AI141003–03S1, NIH/NIAID R01AI158013, NIH/NIAID K23AI134327, and NINDS 1R01NS136197-01.
    • Comments:
      Update of: medRxiv. 2023 Dec 29:2023.10.24.23297114. doi: 10.1101/2023.10.24.23297114. (PMID: 37961239)
    • Grant Information:
      K23 AI157875 United States AI NIAID NIH HHS; L30 AI147159 United States AI NIAID NIH HHS; R01 NS136197 United States NS NINDS NIH HHS; R21 AI167648 United States AI NIAID NIH HHS
    • Accession Number:
      0 (Antigens, Viral)
      0 (Antibodies, Viral)
    • Publication Date:
      Date Created: 20240411 Date Completed: 20240524 Latest Revision: 20240616
    • Publication Date:
      20240616
    • Accession Number:
      10.1016/S1473-3099(24)00211-1
    • Accession Number:
      38604216